Flag of the European Union EU Clinical Trials Register Help

Clinical trials for decitabine OR 2

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38,657 result(s) found for: decitabine OR 2. Displaying page 1,515 of 1,933.
    EudraCT Number: 2021-001213-36 Sponsor Protocol Number: ISTH-02-211 Start Date*: 2021-06-20
    Sponsor Name:Isarna Therapeutics GmbH
    Full Title: TGF-BETa 2 antisense ISTH0036 for the Treatment of diabetic macular Edema (DME) and neovascular age-related maculaR degeneration (nAMD) The “BETTER” Study
    Medical condition: Neovascular age-related macular degeneration (nAMD) Diabetic Macular edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002311-64 Sponsor Protocol Number: SuloPrima Start Date*: 2021-10-01
    Sponsor Name:ALFASIGMA CZECH s.r.o.
    Full Title: Efficacy and safety of sulodexide in the treatment of chronic primary venous disease of the lower extremities: randomized double-blind placebo-controlled clinical trial
    Medical condition: Chronic primary venous disease of the lower limbs
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10066682 Chronic venous insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-002923-37 Sponsor Protocol Number: 2022-ENT-FESS-nonFESS Start Date*: 2023-04-25
    Sponsor Name:Department of Otorhinolaryngology Head & Neck and Audiology, Rigshospitalet, Copenhagen, Denmark
    Full Title: Optimisation of treatment in patients with CRSwNP. An RCT of mepolizumab and surgical treatment with FESS and mepolizumab versus only mepolizumab over a 6- and 12-month follow-up
    Medical condition: Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038738 - Respiratory, thoracic and mediastinal disorders 10080060 Chronic rhinosinusitis with nasal polyps PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002517-18 Sponsor Protocol Number: PROICM2020-04GAB Start Date*: 2020-10-19
    Sponsor Name:Institut régional du cancer de Montpellier (ICM)
    Full Title: Phase II study evaluating the benefit of sequential treatment with Gemcitabine/Nab-Paclitaxel (Gembrax) then Folfirinox followed by adaptative MRI-guided stereotactic radiotherapy in patients with ...
    Medical condition: Locally advanced adenocarcinoma of pancreas
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033600 Pancreatic adenocarcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002145-37 Sponsor Protocol Number: 49RC19_0016 Start Date*: 2019-12-26
    Sponsor Name:University Hospital of Angers (CHU d'Angers)
    Full Title: MIVAR - Milrinone Infusion for VAsospam treatment in subarachnoid hemoRrhage
    Medical condition: hémorragies méningées ou sous-arachnoïdiennes avec vasospasme
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10047164 Vasospasm cerebral LLT
    20.1 100000004852 10042320 Subarachnoid hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001337-13 Sponsor Protocol Number: 2019-01 Start Date*: 2020-03-18
    Sponsor Name:GETAID
    Full Title: USTekinumab in fistulising Perianal Crohn’s Disease: The USTAP CD study
    Medical condition: patient with moderate to severe Crohn’s disease with at least one active perianal fistula track
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001692-13 Sponsor Protocol Number: APHP210082 Start Date*: 2022-08-26
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (APHP)
    Full Title: Early discontinuation of steroid treatment in negative FDG-PET/CT patients with idiopathic retroperitoneal fibrosis. A prospective multicentric study
    Medical condition: Idiopathic retroperitoneal fibrosis (IRF)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10021244 Idiopathic retroperitoneal fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001050-22 Sponsor Protocol Number: DOLPHIN Start Date*: 2020-09-16
    Sponsor Name:Universitätsmedizin Mainz, Interdisziplinäres Zentrum klinische Studien
    Full Title: A Phase II randomized Study to evaluate the efficacy and safety of Cisplatin or Carboplatin / Etoposide and concomitant Radiotherapy combined with Durvalumab followed by Maintenance Therapy with Du...
    Medical condition: Limited Disease Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041069 Small cell lung cancer limited stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006220-40 Sponsor Protocol Number: 2022-0101-01 Start Date*: 2022-06-30
    Sponsor Name:Hvidovre Hospital, Department of Gynecology
    Full Title: Double-blinded randomized placebo-controlled trial on tacrolimus in women with an euploid pregnancy loss and PCOS and/or thyroid autoimmunity
    Medical condition: Polycystic ovarian syndrome and/or thyroid autoimmunity in combination with an euploid pregnancy loss
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    21.0 100000004848 10069094 Thyroid peroxidase antibody positive LLT
    20.1 100000004848 10060326 Thyroglobulin antibody positive LLT
    22.1 100000004868 10072314 Pregnancy loss LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002645-37 Sponsor Protocol Number: KC706-C05 Start Date*: 2006-08-25
    Sponsor Name:Kémia, Inc.
    Full Title: A Phase II randomized double-blind placebo-controlled Study of KC706 in patients with rheumatoid arthritis inadequately controlled with a stable dose of methotrexate
    Medical condition: Active rheumatoid arthritis (RA), patients taking stable doses of methotrexate
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000924-32 Sponsor Protocol Number: AGMT_MM-3 Start Date*: 2018-12-07
    Sponsor Name:AGMT gGmbH
    Full Title: Denosumab for high risk SMM and SLiM CRAB positive, early myeloma patients- a randomized, placebo controlled phase II trial “DEFENCE” (DEnosumab For the rEductioN of the smoldering myeloma transfor...
    Medical condition: High-risk smouldering multiple myeloma or "SLiM CRAB" positive early multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10067386 Multiple myeloma transformation LLT
    20.0 100000004864 10075894 Smoldering myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001999-38 Sponsor Protocol Number: TNF-K-006 Start Date*: 2013-10-07
    Sponsor Name:Neovacs SA
    Full Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy of Neovacs’ TNF-Kinoid in Adult Subjects with Active Rheumatoid Arthritis despite Methotrexate Therapy
    Medical condition: Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001645-12 Sponsor Protocol Number: ALPHA2PREVENT Start Date*: 2021-06-28
    Sponsor Name:Oslo University Hospital
    Full Title: Alpha 2 adrenergic receptor agonists for the prevention of delirium and cognitive decline after open heart surgery (ALPHA2PREVENT): randomised controlled trial.
    Medical condition: Postoperative delirium and cognitive decline in male and female participants aged 70+ scheduled for open heart surgery
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001015-23 Sponsor Protocol Number: APHP180668 Start Date*: 2020-05-13
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing cholangitis with persistent cholestasis despite ursodeoxyc...
    Medical condition: Adult patients with primary sclerosing cholangitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001576-30 Sponsor Protocol Number: 15783408 Start Date*: 2016-11-07
    Sponsor Name:CHU TOULOUSE
    Full Title: Interest of Intra-nodal injection of gentamicin for the treatment of suppurated cat scratch disease’s lymphadenitis: a randomized controlled study. "BIGG" : Bartonellosis and intra-nodal injection...
    Medical condition: Bartonellosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10004145 Bartonellosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002508-42 Sponsor Protocol Number: SBMASTER Start Date*: 2019-12-19
    Sponsor Name:Aarhus University Hospital
    Full Title: A randomized, multicenter, double-blind, placebo-controlled comparison of standard (neo)adjuvant therapy plus placebo versus standard (neo)adjuvant therapy plus atorvastatin in patients with early ...
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003621-10 Sponsor Protocol Number: IC2011.05 Start Date*: 2012-01-19
    Sponsor Name:INSTITUT CURIE
    Full Title: CONSERVATIVE TREATMENT OF PATIENTS WITH RETINOBLASTOMA
    Medical condition: RETINOBLASTOMA
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10038918 Retinoblastoma NOS LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004987-24 Sponsor Protocol Number: APHP180612 Start Date*: 2021-02-18
    Sponsor Name:Assistance Publique-Hopitaux de Paris
    Full Title: Baricitinib in patients with relapsing or naïve dermatomyositis
    Medical condition: Baricitinib in patients with relapsing or naïve dermatomyositis.Multicenter trial, double blind randomized controlled trial with 2 parallel groups. This is an add-on trial with intention to treat a...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10001403 Adult dermatomyositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003092-18 Sponsor Protocol Number: 69HCL19_0588 Start Date*: 2019-11-18
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Pilot and Phase 2 Study of the Efficacy of a Treatment Protocol With Dexamethasone Implant Loading Dose in Patients With Diabetic Macular Edema (LOADEX)
    Medical condition: Oedème maculaire diabétique
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000599-38 Sponsor Protocol Number: RC20_0007 Start Date*: 2020-11-26
    Sponsor Name:NANTES CHU
    Full Title: A phase I/II study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of FR104, a novel antagonist pegylated anti-CD28 Fab’ antibody fragment in de novo renal trans...
    Medical condition: Kidney transplant
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004863 10051366 Kidney graft dysfunction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 19:38:23 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA